Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Vice President, Health Policy | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 226,238 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 11,330 · Balance 230,016 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 3,778 · Balance 226,238 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 23,162 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · derivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,162 Underlying: Class A Common Stock · 23,162 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,741 | $3.84 | $14,365.44 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,163 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 11,218 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,904 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 40,625 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,686 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,778 | $3.84 | $14,507.52 |
DisclosureSEC source: 0002064832-26-000092 · form4a.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,238 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 11,330 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000092 · form4a.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,016 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,523 | $3.73 | $13,140.79 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,061 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 4,100 | $3.73 | $15,293.00 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,584 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 9,607 | $3.73 | $35,834.11 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,684 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,389 | $3.73 | $5,180.97 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,291 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:53 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 43,956 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003231 · form4.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,956 Underlying: Class A Common Stock · 43,956 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:53 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 42,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003231 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,680 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 16, 2025 Filed Feb 19, 2025 19:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 719 | $3.70 | $2,660.30 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,187 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,252 | $3.70 | $4,632.40 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,906 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 8,657 | $3.70 | $32,030.90 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,158 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,453 | $3.70 | $12,776.10 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,815 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:22 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,752 | $2.80 | $4,905.60 |
DisclosureSEC source: 0001062993-24-007932 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,268 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 79,068 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004315 · form4.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,068 Underlying: Class A Common Stock · 79,068 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 43,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004315 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,020 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 20:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 719 | $3.48 | $2,502.12 |
DisclosureSEC source: 0001062993-24-003767 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,288 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,252 | $3.68 | $4,607.36 |
DisclosureSEC source: 0001062993-24-003767 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,007 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 8,657 | $3.68 | $31,857.76 |
DisclosureSEC source: 0001062993-24-003767 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,259 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:21 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,097 | $2.13 | $4,466.61 |
DisclosureSEC source: 0001062993-23-008510 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,916 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 118,035 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004892 · form4.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,035 Underlying: Class A Common Stock · 118,035 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 99,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004892 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,013 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 717 | $2.75 | $1,971.75 |
DisclosureSEC source: 0001062993-23-004061 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,585 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,249 | $2.92 | $3,647.08 |
DisclosureSEC source: 0001062993-23-004061 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,302 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 18:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,738 | $7.89 | $21,602.82 |
DisclosureSEC source: 0001062993-22-009813 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,551 Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 18:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,401 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001062993-22-007530 · form4.xml · derivative · entry 6 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,175 Underlying: Class A Common Stock · 22,401 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 18:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 46,103 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001062993-22-007530 · form4.xml · derivative · entry 5 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,397 Underlying: Class A Common Stock · 46,103 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 18:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 97,436 | $8.39 | $817,488.04 |
DisclosureSEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,289 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.42, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 18:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 22,401 | $3.46 | $77,507.46 |
DisclosureSEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 18:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 46,103 | $3.46 | $159,516.38 |
DisclosureSEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 18:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 10,000 | $8.52 | $85,200.00 |
DisclosureSEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,221 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 18:59 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 718 | $7.78 | $5,586.04 |
DisclosureSEC source: 0001062993-22-004804 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,221 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:59 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 34,112 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001062993-22-004804 · form4.xml · derivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,112 Underlying: Class A Common Stock · 34,112 shares Expires 2032-02-15 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:59 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 14,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004804 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,939 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:43 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,770 | $19.83 | $35,099.10 |
DisclosureSEC source: 0000899243-21-014956 · doc4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,556 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 63,246 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001661181-21-000033 · edgar.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,246 Underlying: Class A Common Stock · 63,246 shares Expires 2031-02-16 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 8,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000033 · edgar.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,326 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 07:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 158,967 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-20-000006 · edgar.xml · derivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,967 Underlying: Class A Common Stock · 158,967 shares Expires 2030-04-22 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 07:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 24,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000006 · edgar.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,066 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| January 21, 2020 Filed Apr 24, 2020 07:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,450 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001661181-20-000006 · edgar.xml · derivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,450 shares Expires 2020-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 21, 2020 Filed Apr 24, 2020 07:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 30,450 | $1.70 | $51,765.00 |
DisclosureSEC source: 0001661181-20-000006 · edgar.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 20:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 101,500 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000043 · edgar.xml · derivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,500 Underlying: Common Stock · 101,500 shares Expires 2027-05-04 F7 · price: Received in connection with the Merger in exchange for an option to acquire 50,000 shares of common stock of Organogenesis for $7.01 per share. F6 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 20:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 100,576 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000043 · edgar.xml · derivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,576 Underlying: Common Stock · 100,576 shares Expires 2027-05-04 F5 · price: Received in connection with the Merger in exchange for an option to acquire 49,545 shares of common stock of Organogenesis for $7.01 per share. F4 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 20:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 30,450 | Not disclosed Strike: $1.70 | Not disclosed |
DisclosureSEC source: 0001661181-18-000043 · edgar.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,450 Underlying: Common Stock · 30,450 shares Expires 2020-02-22 F3 · price: Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $3.45 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 20:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantCommon Stock | 8,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001661181-18-000043 · edgar.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,482 F1 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 4,178 shares of common stock of Organogenesis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.